To enact sections 3902.65 and 5164.13 of the Revised Code to require health benefit plan and Medicaid program coverage of biomarker testing.
HB8 would require Ohio health benefit plans and the Medicaid program to cover biomarker testing when the test is ordered by a qualified treating provider and is medically necessary for diagnosis, treatment, or ongoing monitoring of a disease or condition. The bill defines biomarker and biomarker testing broadly, including tissue, blood, and other biospecimen analysis, and it covers a range of test types such as single-analyte tests, multiplex panels, and genomic sequencing. Coverage is limited to testing supported by medical or scientific evidence, including FDA labeling, FDA-approved drug indications, CMS coverage determinations, nationally recognized clinical practice guidelines, and peer-reviewed studies showing improved health outcomes.
The bill also requires coverage to be provided in a way that minimizes disruptions in care, including avoiding the need for multiple biopsies or biospecimen samples where possible. It establishes that appeals of coverage denials must follow existing insurer or Medicaid appeal procedures and be accessible in writing and online to providers and recipients. The bill expressly states that it does not require coverage for biomarker testing used solely for screening purposes.
If enacted, HB8 would add new sections 3902.65 and 5164.13 to the Revised Code and would impose new coverage mandates on both private health benefit plans and Medicaid. It would affect insurers, Medicaid administrators, providers ordering biomarker tests, and patients who may benefit from precision medicine or targeted treatment decisions. The bill also includes legislative intent language saying the goal is to improve health outcomes and reduce long-term costs, while avoiding price inflation by test manufacturers and administrators.
The general sentiment reflected in the available voting history appears favorable, as the bill received a House favorable passage vote of 10-3 in committee. No committee transcript was provided, so there is no recorded debate to indicate broader public or member concerns beyond the vote itself. The committee result suggests support for expanding access to medically necessary biomarker testing, though the negative votes indicate some opposition or reservations.
The main point of contention appears to be the cost and market effects of a new coverage mandate. The bill’s intent section specifically warns against allowing biomarker test manufacturers and administrators to substantially increase prices because of the new coverage requirements, suggesting lawmakers were concerned about premium growth, Medicaid spending, or provider/test pricing. Another likely area of concern is the scope of mandated coverage, especially how medical necessity and evidence standards will be applied in practice, though the bill attempts to narrow that by excluding screening-only tests and tying coverage to recognized evidence sources.
HB8 would create new statutory coverage requirements in Ohio law for biomarker testing under both private health benefit plans and Medicaid. It would add sections 3902.65 and 5164.13 to the Revised Code, requiring coverage for medically necessary biomarker tests used for diagnosis, treatment, and monitoring, while excluding screening-only use. The bill would also require insurers and Medicaid to maintain accessible appeal processes and to structure coverage in a way that reduces care disruptions, including repeated biopsies or sample collection. In practical terms, it would expand access to precision-medicine testing for patients and impose new benefit obligations on insurers, Medicaid, and related administrators.
The available legislative history suggests generally supportive sentiment toward the bill’s goal of expanding access to biomarker testing. The House committee vote of 10-3 indicates the measure advanced with a clear majority, implying broad agreement on the value of medically necessary testing and its potential to improve outcomes. At the same time, the presence of three nays shows that some members had reservations, likely tied to cost, utilization, or implementation concerns. No transcript was provided, so the record does not show detailed debate or stakeholder testimony.
The most notable contention is likely the financial impact of a mandated coverage expansion. The bill’s own intent language addresses concern that manufacturers and administrators of biomarker tests could raise prices in response to guaranteed coverage, indicating lawmakers were trying to preempt cost escalation. Another possible point of disagreement is the breadth of the coverage standard, especially the reliance on medical necessity and evidence-based criteria, which may raise questions about who decides when a biomarker test qualifies. Opponents may also be concerned about administrative burden for insurers and Medicaid, while supporters are likely focused on improved diagnosis, targeted treatment, and better health outcomes.